Electra Therapeutics CMO reports 309,676 options

Chief Medical Officer Dao Kim-Hien discloses multiple option positions in ETRA, with time-based vesting and early-exercise features.

Rhea-AI Filing Summary

Electra Therapeutics, Inc. (ETRA) reported an initial statement of beneficial ownership for Chief Medical Officer Dao Kim-Hien, detailing holdings of employee stock options to purchase common stock. The positions include options over 62,631 and 23,634 shares at $4.40, 103,992 and 47,269 shares at $5.05, 309,676 shares at $4.96, and 155,979 shares at $15.00, expiring between 2033 and 2036. Footnotes state these options vest over time in monthly installments and are early exercisable, subject to the issuer’s right of repurchase.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Dao Kim-Hien

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (right to buy) F1	--	--	--
holding	Employee Stock Option (right to buy) F2	--	--	--
holding	Employee Stock Option (right to buy) F3	--	--	--
holding	Employee Stock Option (right to buy) F4	--	--	--
holding	Employee Stock Option (right to buy) F5	--	--	--
holding	Employee Stock Option (right to buy) F6	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 703,181 contracts (Direct)

Footnotes (6)

1. F1. 1/4th of the total shares subject to this option vested one year after April 3, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
2. F2. 1/4th of the total shares subject to this option vested one year after January 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
3. F3. 1/4th of the total shares subject to this option vested one year after May 16, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
4. F4. 1/4th of the total shares subject to this option vested one year after November 14, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
5. F5. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
6. F6. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

Key Figures

Option exercise price: $4.40 Underlying shares at $4.40: 62,631 shares and 23,634 shares Underlying shares at $5.05: 103,992 shares and 47,269 shares +4 more

7 metrics

Option exercise price $4.40 Employee stock options expiring August 8, 2033 and November 16, 2033

Underlying shares at $4.40 62,631 shares and 23,634 shares Employee stock options held directly by Dao Kim-Hien

Underlying shares at $5.05 103,992 shares and 47,269 shares Employee stock options expiring May 8, 2034 and November 13, 2034

Largest option position 309,676 shares at $4.96 Employee stock option expiring February 12, 2036

High-strike option 155,979 shares at $15.00 Employee stock option expiring September 16, 2036

Standard vesting fraction 1/48th monthly Monthly vesting installments for several option grants

Initial cliff vesting 1/4th after one year Cliff vesting one year after specified grant-related dates

Key Terms

Employee Stock Option (right to buy), early exercisable, right of repurchase, vesting

4 terms

Employee Stock Option (right to buy) financial

"security title is listed as Employee Stock Option (right to buy)"

early exercisable financial

"The shares subject to this option are early exercisable, subject to the Issuer's right"

right of repurchase financial

"early exercisable, subject to the Issuer's right of repurchase"

vesting financial

"1/4th of the total shares subject to this option vested one year after"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for ETRA disclose about Dao Kim-Hien?

The Form 3 shows that Chief Medical Officer Dao Kim-Hien holds several employee stock options to purchase Electra Therapeutics (ETRA) common stock, with different exercise prices, expiration dates through 2036, and time-based vesting schedules.

What stock option positions in ETRA at a $4.40 exercise price are reported?

Dao Kim-Hien holds employee stock options with a $4.40 exercise price covering 62,631 underlying shares expiring on August 8, 2033 and 23,634 underlying shares expiring on November 16, 2033, all held directly.

What ETRA options at a $5.05 exercise price does the CMO hold?

The filing lists options with a $5.05 exercise price for 103,992 underlying shares expiring on May 8, 2034 and 47,269 underlying shares expiring on November 13, 2034, subject to time-based vesting and early exercise with issuer repurchase rights.

What is the largest ETRA option position disclosed for Dao Kim-Hien?

The largest single position is an employee stock option with a $4.96 exercise price over 309,676 underlying shares of common stock, expiring on February 12, 2036, vesting monthly starting from February 1, 2026 and described as early exercisable with a repurchase right.

Are any high-strike ETRA options reported for the CMO?

Yes. An employee stock option with a $15.00 exercise price covers 155,979 underlying shares of common stock, expiring on September 16, 2036, with vesting in 1/48th monthly installments commencing on September 17, 2026.

How do the ETRA options held by Dao Kim-Hien vest?

For several grants, 1/4th of the shares vested one year after specified start dates, with 1/48th vesting monthly thereafter; other grants vest 1/48th monthly from stated commencement dates. Many are early exercisable, subject to the issuer’s right of repurchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 08:25 PM Accepted by SEC EDGAR 09/18/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dao Kim-Hien

(Last) (First) (Middle)

C/O ELECTRA THERAPEUTICS, INC.

230 E GRAND AVENUE, SUITE S-100

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2026

3. Issuer Name and Ticker or Trading Symbol
Electra Therapeutics, Inc. [ ETRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(1)	08/08/2033	Common Stock	62,631	$4.4	D
Employee Stock Option (right to buy)	(2)	11/16/2033	Common Stock	23,634	$4.4	D
Employee Stock Option (right to buy)	(3)	05/08/2034	Common Stock	103,992	$5.05	D
Employee Stock Option (right to buy)	(4)	11/13/2034	Common Stock	47,269	$5.05	D
Employee Stock Option (right to buy)	(5)	02/12/2036	Common Stock	309,676	$4.96	D
Employee Stock Option (right to buy)	(6)	09/16/2036	Common Stock	155,979	$15	D

Explanation of Responses:

1. 1/4th of the total shares subject to this option vested one year after April 3, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

2. 1/4th of the total shares subject to this option vested one year after January 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

3. 1/4th of the total shares subject to this option vested one year after May 16, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

4. 1/4th of the total shares subject to this option vested one year after November 14, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

5. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

6. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.

	/s/ Jamie Kitano, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)